Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash & Current Investments (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Cash & Current Investments data on record, last reported at $184.2 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 94.27% year-over-year to $184.2 million; the TTM value through Dec 2025 reached $184.2 million, up 94.27%, while the annual FY2025 figure was $184.2 million, 94.27% up from the prior year.
  • Cash & Current Investments reached $184.2 million in Q4 2025 per TARS's latest filing, down from $401.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $407.9 million in Q1 2025 and bottomed at $94.8 million in Q4 2024.
  • Average Cash & Current Investments over 5 years is $240.8 million, with a median of $221.8 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: soared 232.55% in 2021, then crashed 58.31% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $171.8 million in 2021, then grew by 26.31% to $217.0 million in 2022, then grew by 4.8% to $227.4 million in 2023, then plummeted by 58.31% to $94.8 million in 2024, then surged by 94.27% to $184.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $184.2 million in Q4 2025, $401.8 million in Q3 2025, and $381.1 million in Q2 2025.